List All Esophageal Cancer Trials

Esophageal Cancer

 

Pembrolizumab vs. Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (20160019)
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine

Investigator: Andrew Coveler, MD;   Conditions: Esophageal Cancer; Gastrointestinal Cancer; Adenocarcinoma;    Status: Recruiting;   Study ID: NCT02370498